The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Viking Therapeutics Inc. (NASDAQ:VKTX) is one of the 10 best mid-cap stocks that could double your money.

On May 28, Lake Street assigned a Buy rating to Viking Therapeutics Inc. (NASDAQ:VKTX) while setting a price target at $89. This leads to an upside potential of more than 211% at the prevailing level.

RAJ CREATIONZS / shutterstock.com

According to the firm, this stance is driven by the market opportunity for VK2735, the company’s lead clinical asset for obesity. VK2735 is projected to generate approximately $3 billion in risk-adjusted worldwide sales by the year 2040. Additionally, the firm noted the potential for further financial upside stemming from the company’s earlier-stage pipeline assets.

On May 27, Truist published a report on Viking Therapeutics Inc. (NASDAQ:VKTX) with a Buy rating and a price target of $83, indicating a 191% upside. The firm highlighted the company as a distinct competitor within a crowded and highly aggressive obesity treatment market.

The company effectively addresses two major hurdles found in existing and emerging treatments, which include long-term patient compliance and rapid time to efficacy, pointing to the achievement of 14.7% weight loss within 13 weeks without hitting a plateau.

Furthermore, Truist emphasized that by offering both the oral and subcutaneous delivery options, the company enables a continuous care model with adaptable dosing and flexible titration. This versatility allows for greater clinical personalization while helping to reduce gastrointestinal side effects.

Viking Therapeutics Inc. (NASDAQ:VKTX) specializes in metabolic and endocrine disorder therapies. As a clinical-stage biopharmaceutical company, they direct their research efforts towards small-molecule drugs to cure obesity, fatty liver, and diabetes.

While we acknowledge the potential of VKTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.